Non-serious adverse events
|
Levosimendan |
Placebo |
Total subjects affected by non serious adverse events
|
|
|
subjects affected / exposed
|
312 / 326 (95.71%) |
157 / 166 (94.58%) |
Vascular disorders
|
|
|
ARTERIOSCLEROSIS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
DEEP VEIN THROMBOSIS
|
|
|
subjects affected / exposed
|
5 / 326 (1.53%) |
3 / 166 (1.81%) |
occurrences all number
|
5 |
3 |
HAEMATOMA
|
|
|
subjects affected / exposed
|
4 / 326 (1.23%) |
4 / 166 (2.41%) |
occurrences all number
|
4 |
4 |
HOT FLUSH
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
HYPERTENSION
|
|
|
subjects affected / exposed
|
8 / 326 (2.45%) |
9 / 166 (5.42%) |
occurrences all number
|
8 |
10 |
HYPOTENSION
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
2 / 166 (1.20%) |
occurrences all number
|
4 |
2 |
ILIAC ARTERY STENOSIS
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
2 |
ORTHOSTATIC HYPOTENSION
|
|
|
subjects affected / exposed
|
5 / 326 (1.53%) |
0 / 166 (0.00%) |
occurrences all number
|
5 |
0 |
PERIPHERAL COLDNESS
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
3 / 166 (1.81%) |
occurrences all number
|
0 |
3 |
RAYNAUD'S PHENOMENON
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
THROMBOSIS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
VENOUS THROMBOSIS LIMB
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
Surgical and medical procedures
|
|
|
CENTRAL VENOUS CATHETERISATION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
DENTAL IMPLANTATION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
GASTROSTOMY
|
|
|
subjects affected / exposed
|
4 / 326 (1.23%) |
1 / 166 (0.60%) |
occurrences all number
|
5 |
1 |
MECHANICAL VENTILATION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
Pregnancy, puerperium and perinatal conditions
|
|
|
CEPHALHAEMATOMA
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
General disorders and administration site conditions
|
|
|
ASTHENIA
|
|
|
subjects affected / exposed
|
16 / 326 (4.91%) |
1 / 166 (0.60%) |
occurrences all number
|
19 |
1 |
CATHETER SITE BRUISE
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
CATHETER SITE HAEMORRHAGE
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
CATHETER SITE PAIN
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
CHEST DISCOMFORT
|
|
|
subjects affected / exposed
|
4 / 326 (1.23%) |
4 / 166 (2.41%) |
occurrences all number
|
6 |
4 |
CHEST PAIN
|
|
|
subjects affected / exposed
|
9 / 326 (2.76%) |
4 / 166 (2.41%) |
occurrences all number
|
12 |
6 |
CHILLS
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
2 / 166 (1.20%) |
occurrences all number
|
2 |
2 |
CYST
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
DISCOMFORT
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
DISEASE PROGRESSION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
FATIGUE
|
|
|
subjects affected / exposed
|
30 / 326 (9.20%) |
10 / 166 (6.02%) |
occurrences all number
|
33 |
11 |
FEELING COLD
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
FEELING JITTERY
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
GAIT DISTURBANCE
|
|
|
subjects affected / exposed
|
9 / 326 (2.76%) |
2 / 166 (1.20%) |
occurrences all number
|
9 |
2 |
INFLUENZA LIKE ILLNESS
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
0 / 166 (0.00%) |
occurrences all number
|
3 |
0 |
MALAISE
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
MEDICAL DEVICE PAIN
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
MEDICAL DEVICE SITE ERYTHEMA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
MEDICAL DEVICE SITE HAEMORRHAGE
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
NON-CARDIAC CHEST PAIN
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
OEDEMA
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
OEDEMA PERIPHERAL
|
|
|
subjects affected / exposed
|
26 / 326 (7.98%) |
12 / 166 (7.23%) |
occurrences all number
|
28 |
14 |
PAIN
|
|
|
subjects affected / exposed
|
11 / 326 (3.37%) |
2 / 166 (1.20%) |
occurrences all number
|
12 |
2 |
PARADOXICAL DRUG REACTION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
PERIPHERAL SWELLING
|
|
|
subjects affected / exposed
|
7 / 326 (2.15%) |
3 / 166 (1.81%) |
occurrences all number
|
7 |
4 |
PYREXIA
|
|
|
subjects affected / exposed
|
4 / 326 (1.23%) |
4 / 166 (2.41%) |
occurrences all number
|
5 |
5 |
SECRETION DISCHARGE
|
|
|
subjects affected / exposed
|
4 / 326 (1.23%) |
3 / 166 (1.81%) |
occurrences all number
|
4 |
3 |
SWELLING FACE
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
VESSEL PUNCTURE SITE BRUISE
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
Immune system disorders
|
|
|
ALLERGY TO ARTHROPOD BITE
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
CONTRAST MEDIA ALLERGY
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
DRUG HYPERSENSITIVITY
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
SEASONAL ALLERGY
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
2 / 166 (1.20%) |
occurrences all number
|
1 |
2 |
Social circumstances
|
|
|
LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
Reproductive system and breast disorders
|
|
|
BENIGN PROSTATIC HYPERPLASIA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
ERECTILE DYSFUNCTION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
MENOPAUSAL SYMPTOMS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
MENSTRUATION IRREGULAR
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
PROSTATITIS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
PROSTATOMEGALY
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
Respiratory, thoracic and mediastinal disorders
|
|
|
ACUTE RESPIRATORY FAILURE
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
ATELECTASIS
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
BRONCHITIS CHRONIC
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
BRONCHOSPASM
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
CHOKING
|
|
|
subjects affected / exposed
|
5 / 326 (1.53%) |
2 / 166 (1.20%) |
occurrences all number
|
5 |
2 |
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
COUGH
|
|
|
subjects affected / exposed
|
16 / 326 (4.91%) |
13 / 166 (7.83%) |
occurrences all number
|
19 |
15 |
COUGH DECREASED
|
|
|
subjects affected / exposed
|
4 / 326 (1.23%) |
0 / 166 (0.00%) |
occurrences all number
|
4 |
0 |
DIAPHRAGM MUSCLE WEAKNESS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
DIAPHRAGMATIC PARALYSIS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
DIAPHRAGMATIC SPASM
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
0 / 166 (0.00%) |
occurrences all number
|
3 |
0 |
DYSPHONIA
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
0 / 166 (0.00%) |
occurrences all number
|
3 |
0 |
DYSPNOEA
|
|
|
subjects affected / exposed
|
54 / 326 (16.56%) |
30 / 166 (18.07%) |
occurrences all number
|
61 |
35 |
DYSPNOEA AT REST
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
DYSPNOEA EXERTIONAL
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
EMPHYSEMA
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
EPISTAXIS
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
2 / 166 (1.20%) |
occurrences all number
|
0 |
2 |
HYPERACTIVE PHARYNGEAL REFLEX
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
HYPERVENTILATION
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
HYPOVENTILATION
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
1 / 166 (0.60%) |
occurrences all number
|
3 |
1 |
HYPOXIA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
INCREASED BRONCHIAL SECRETION
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
3 |
0 |
INCREASED UPPER AIRWAY SECRETION
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
1 / 166 (0.60%) |
occurrences all number
|
2 |
1 |
INCREASED VISCOSITY OF UPPER RESPIRATORY SECRETION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
LARYNGOSPASM
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
NASAL CONGESTION
|
|
|
subjects affected / exposed
|
5 / 326 (1.53%) |
4 / 166 (2.41%) |
occurrences all number
|
5 |
4 |
NASAL DRYNESS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
NASAL POLYPS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
NASAL PRURITUS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
OROPHARYNGEAL PAIN
|
|
|
subjects affected / exposed
|
5 / 326 (1.53%) |
6 / 166 (3.61%) |
occurrences all number
|
5 |
6 |
ORTHOPNOEA
|
|
|
subjects affected / exposed
|
6 / 326 (1.84%) |
3 / 166 (1.81%) |
occurrences all number
|
6 |
3 |
PHARYNGEAL ERYTHEMA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
PLEURAL EFFUSION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
PNEUMONIA ASPIRATION
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
2 / 166 (1.20%) |
occurrences all number
|
0 |
2 |
PRODUCTIVE COUGH
|
|
|
subjects affected / exposed
|
4 / 326 (1.23%) |
3 / 166 (1.81%) |
occurrences all number
|
5 |
3 |
PULMONARY CONGESTION
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
PULMONARY EMBOLISM
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
2 |
1 |
PULMONARY MASS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
RESPIRATORY FAILURE
|
|
|
subjects affected / exposed
|
17 / 326 (5.21%) |
12 / 166 (7.23%) |
occurrences all number
|
17 |
12 |
RESPIRATORY MUSCLE WEAKNESS
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
3 / 166 (1.81%) |
occurrences all number
|
2 |
3 |
RESPIRATORY TRACT CONGESTION
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
RHINITIS ALLERGIC
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
1 / 166 (0.60%) |
occurrences all number
|
2 |
1 |
RHINORRHOEA
|
|
|
subjects affected / exposed
|
4 / 326 (1.23%) |
1 / 166 (0.60%) |
occurrences all number
|
4 |
1 |
SINUS CONGESTION
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
2 / 166 (1.20%) |
occurrences all number
|
0 |
2 |
SLEEP APNOEA SYNDROME
|
|
|
subjects affected / exposed
|
5 / 326 (1.53%) |
3 / 166 (1.81%) |
occurrences all number
|
6 |
3 |
SPUTUM RETENTION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
UPPER RESPIRATORY TRACT CONGESTION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
UPPER-AIRWAY COUGH SYNDROME
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
VOCAL CORD DYSFUNCTION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
WHEEZING
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
Psychiatric disorders
|
|
|
ABNORMAL DREAMS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
ADJUSTMENT DISORDER WITH DEPRESSED MOOD
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
AFFECT LABILITY
|
|
|
subjects affected / exposed
|
6 / 326 (1.84%) |
4 / 166 (2.41%) |
occurrences all number
|
6 |
4 |
AFFECTIVE DISORDER
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
AGITATION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
ANXIETY
|
|
|
subjects affected / exposed
|
18 / 326 (5.52%) |
6 / 166 (3.61%) |
occurrences all number
|
18 |
6 |
CONFUSIONAL STATE
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
DEPRESSED MOOD
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
DEPRESSION
|
|
|
subjects affected / exposed
|
13 / 326 (3.99%) |
4 / 166 (2.41%) |
occurrences all number
|
13 |
4 |
FEAR
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
HALLUCINATION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
INITIAL INSOMNIA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
INSOMNIA
|
|
|
subjects affected / exposed
|
22 / 326 (6.75%) |
10 / 166 (6.02%) |
occurrences all number
|
22 |
10 |
MENTAL DISORDER
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
MIDDLE INSOMNIA
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
PANIC ATTACK
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
RESTLESSNESS
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
SLEEP DISORDER
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
2 / 166 (1.20%) |
occurrences all number
|
2 |
2 |
STRESS
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
TENSION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
Product issues
|
|
|
DEVICE OCCLUSION
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
Hepatobiliary disorders
|
|
|
CHOLECYSTITIS
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
Investigations
|
|
|
ALANINE AMINOTRANSFERASE INCREASED
|
|
|
subjects affected / exposed
|
6 / 326 (1.84%) |
3 / 166 (1.81%) |
occurrences all number
|
7 |
3 |
ASPARTATE AMINOTRANSFERASE INCREASED
|
|
|
subjects affected / exposed
|
4 / 326 (1.23%) |
3 / 166 (1.81%) |
occurrences all number
|
5 |
3 |
BACTERIAL TEST
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
BACTERIAL TEST POSITIVE
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
1 / 166 (0.60%) |
occurrences all number
|
3 |
1 |
BLOOD BILIRUBIN INCREASED
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
BLOOD CALCIUM DECREASED
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
BLOOD CREATINE PHOSPHOKINASE INCREASED
|
|
|
subjects affected / exposed
|
5 / 326 (1.53%) |
2 / 166 (1.20%) |
occurrences all number
|
6 |
2 |
BLOOD FOLATE DECREASED
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
BLOOD GLUCOSE INCREASED
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
2 / 166 (1.20%) |
occurrences all number
|
2 |
2 |
BLOOD POTASSIUM INCREASED
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
BLOOD PRESSURE INCREASED
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
BLOOD PRESSURE ORTHOSTATIC INCREASED
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
BLOOD SODIUM INCREASED
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
BLOOD THYROID STIMULATING HORMONE DECREASED
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
1 / 166 (0.60%) |
occurrences all number
|
2 |
1 |
BLOOD THYROID STIMULATING HORMONE INCREASED
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
BLOOD URINE PRESENT
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
BODY TEMPERATURE INCREASED
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
C-REACTIVE PROTEIN INCREASED
|
|
|
subjects affected / exposed
|
6 / 326 (1.84%) |
3 / 166 (1.81%) |
occurrences all number
|
6 |
3 |
CARDIAC MURMUR
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
ELECTROCARDIOGRAM QT PROLONGED
|
|
|
subjects affected / exposed
|
4 / 326 (1.23%) |
3 / 166 (1.81%) |
occurrences all number
|
4 |
3 |
ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
EOSINOPHIL COUNT INCREASED
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
FORCED VITAL CAPACITY DECREASED
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
GAMMA-GLUTAMYLTRANSFERASE INCREASED
|
|
|
subjects affected / exposed
|
7 / 326 (2.15%) |
3 / 166 (1.81%) |
occurrences all number
|
7 |
3 |
GASTRIC PH DECREASED
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
2 / 166 (1.20%) |
occurrences all number
|
0 |
2 |
GLUCOSE URINE PRESENT
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
HAEMOGLOBIN DECREASED
|
|
|
subjects affected / exposed
|
4 / 326 (1.23%) |
0 / 166 (0.00%) |
occurrences all number
|
4 |
0 |
HEART RATE DECREASED
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
HEART RATE INCREASED
|
|
|
subjects affected / exposed
|
64 / 326 (19.63%) |
5 / 166 (3.01%) |
occurrences all number
|
68 |
5 |
HEPATIC ENZYME INCREASED
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
2 / 166 (1.20%) |
occurrences all number
|
0 |
2 |
INTRAOCULAR PRESSURE INCREASED
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
LYMPHOCYTE COUNT DECREASED
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
MONOCYTE COUNT INCREASED
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
NEUTROPHIL COUNT DECREASED
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
NEUTROPHIL COUNT INCREASED
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
ORTHOSTATIC HEART RATE RESPONSE INCREASED
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
OXYGEN SATURATION DECREASED
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
PLATELET COUNT INCREASED
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
PROTEIN URINE PRESENT
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
PULMONARY FUNCTION TEST DECREASED
|
|
|
subjects affected / exposed
|
7 / 326 (2.15%) |
2 / 166 (1.20%) |
occurrences all number
|
7 |
2 |
RED BLOOD CELL COUNT DECREASED
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
SLOW VITAL CAPACITY DECREASED
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
2 / 166 (1.20%) |
occurrences all number
|
2 |
2 |
TRANSAMINASES INCREASED
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
TROPONIN INCREASED
|
|
|
subjects affected / exposed
|
8 / 326 (2.45%) |
1 / 166 (0.60%) |
occurrences all number
|
9 |
1 |
TROPONIN T INCREASED
|
|
|
subjects affected / exposed
|
10 / 326 (3.07%) |
2 / 166 (1.20%) |
occurrences all number
|
10 |
2 |
URINE ANALYSIS ABNORMAL
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
2 / 166 (1.20%) |
occurrences all number
|
0 |
2 |
URINE LEUKOCYTE ESTERASE POSITIVE
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
VITAL CAPACITY DECREASED
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
WEIGHT DECREASED
|
|
|
subjects affected / exposed
|
26 / 326 (7.98%) |
15 / 166 (9.04%) |
occurrences all number
|
27 |
15 |
WHITE BLOOD CELL COUNT DECREASED
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
WHITE BLOOD CELL COUNT INCREASED
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
2 / 166 (1.20%) |
occurrences all number
|
1 |
2 |
WHITE BLOOD CELLS URINE POSITIVE
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
Injury, poisoning and procedural complications
|
|
|
ANIMAL BITE
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
2 / 166 (1.20%) |
occurrences all number
|
0 |
2 |
ANKLE FRACTURE
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
BACK INJURY
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
BONE CONTUSION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
2 / 166 (1.20%) |
occurrences all number
|
1 |
2 |
BONE FISSURE
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
BURNS SECOND DEGREE
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
CLAVICLE FRACTURE
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
CONCUSSION
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
4 / 166 (2.41%) |
occurrences all number
|
4 |
4 |
CONTUSION
|
|
|
subjects affected / exposed
|
21 / 326 (6.44%) |
8 / 166 (4.82%) |
occurrences all number
|
23 |
9 |
CRANIOCEREBRAL INJURY
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
EYE CONTUSION
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
1 / 166 (0.60%) |
occurrences all number
|
2 |
1 |
EYE INJURY
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
2 / 166 (1.20%) |
occurrences all number
|
1 |
2 |
FACIAL BONES FRACTURE
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
FALL
|
|
|
subjects affected / exposed
|
86 / 326 (26.38%) |
45 / 166 (27.11%) |
occurrences all number
|
150 |
100 |
FIBULA FRACTURE
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
FOOT FRACTURE
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
2 / 166 (1.20%) |
occurrences all number
|
1 |
2 |
GASTROSTOMY TUBE SITE COMPLICATION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
HAND FRACTURE
|
|
|
subjects affected / exposed
|
4 / 326 (1.23%) |
0 / 166 (0.00%) |
occurrences all number
|
4 |
0 |
HEAD INJURY
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
2 |
1 |
HUMERUS FRACTURE
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
HYPHAEMA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
INCISION SITE HAEMATOMA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
INCISION SITE IMPAIRED HEALING
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
JOINT DISLOCATION
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
JOINT INJURY
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
LIGAMENT RUPTURE
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
LIGAMENT SPRAIN
|
|
|
subjects affected / exposed
|
8 / 326 (2.45%) |
2 / 166 (1.20%) |
occurrences all number
|
9 |
2 |
LIMB INJURY
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
3 / 166 (1.81%) |
occurrences all number
|
0 |
3 |
LIP INJURY
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
MUSCLE INJURY
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
MUSCLE STRAIN
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
MUSCULOSKELETAL FOREIGN BODY
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
NASAL INJURY
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
POST LUMBAR PUNCTURE SYNDROME
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
POST-TRAUMATIC PAIN
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
2 / 166 (1.20%) |
occurrences all number
|
2 |
2 |
PROCEDURAL PAIN
|
|
|
subjects affected / exposed
|
5 / 326 (1.53%) |
0 / 166 (0.00%) |
occurrences all number
|
5 |
0 |
RADIUS FRACTURE
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
RIB FRACTURE
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
ROAD TRAFFIC ACCIDENT
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
2 / 166 (1.20%) |
occurrences all number
|
3 |
3 |
SCRATCH
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
SCROTAL HAEMATOMA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
SKIN ABRASION
|
|
|
subjects affected / exposed
|
5 / 326 (1.53%) |
1 / 166 (0.60%) |
occurrences all number
|
7 |
1 |
SKIN INJURY
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
SKIN LACERATION
|
|
|
subjects affected / exposed
|
17 / 326 (5.21%) |
12 / 166 (7.23%) |
occurrences all number
|
20 |
15 |
SPINAL FRACTURE
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
STOMA SITE DISCOMFORT
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
STOMA SITE PAIN
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
STOMA SITE REACTION
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
THERMAL BURN
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
TOOTH FRACTURE
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
UPPER LIMB FRACTURE
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
WOUND
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
WRIST FRACTURE
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
Cardiac disorders
|
|
|
AORTIC VALVE SCLEROSIS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
ATRIAL FIBRILLATION
|
|
|
subjects affected / exposed
|
4 / 326 (1.23%) |
0 / 166 (0.00%) |
occurrences all number
|
4 |
0 |
BRADYCARDIA
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
CARDIAC DISCOMFORT
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
CARDIAC FLUTTER
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
CARDIAC HYPERTROPHY
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
CARDIOMYOPATHY
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
CARDIOVASCULAR DISORDER
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
CORONARY ARTERY DISEASE
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
DIASTOLIC DYSFUNCTION
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
LONG QT SYNDROME
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
MITRAL VALVE INCOMPETENCE
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
MYOCARDIAL INFARCTION
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
MYOCARDIAL ISCHAEMIA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
NODAL RHYTHM
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
PALPITATIONS
|
|
|
subjects affected / exposed
|
17 / 326 (5.21%) |
4 / 166 (2.41%) |
occurrences all number
|
23 |
4 |
SINUS TACHYCARDIA
|
|
|
subjects affected / exposed
|
13 / 326 (3.99%) |
0 / 166 (0.00%) |
occurrences all number
|
14 |
0 |
TACHYCARDIA
|
|
|
subjects affected / exposed
|
32 / 326 (9.82%) |
8 / 166 (4.82%) |
occurrences all number
|
41 |
11 |
TACHYCARDIA PAROXYSMAL
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
1 / 166 (0.60%) |
occurrences all number
|
2 |
1 |
VENTRICULAR EXTRASYSTOLES
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
1 / 166 (0.60%) |
occurrences all number
|
2 |
1 |
VENTRICULAR HYPERTROPHY
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
Nervous system disorders
|
|
|
AGEUSIA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
AMYOTROPHIC LATERAL SCLEROSIS
|
|
|
subjects affected / exposed
|
4 / 326 (1.23%) |
4 / 166 (2.41%) |
occurrences all number
|
4 |
4 |
ATAXIA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
BALANCE DISORDER
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
3 / 166 (1.81%) |
occurrences all number
|
2 |
3 |
BURNING SENSATION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
CERVICAL RADICULOPATHY
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
COGNITIVE DISORDER
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
DEMENTIA
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
DEPRESSED LEVEL OF CONSCIOUSNESS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
DIZZINESS
|
|
|
subjects affected / exposed
|
21 / 326 (6.44%) |
13 / 166 (7.83%) |
occurrences all number
|
35 |
14 |
DROOLING
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
DYSARTHRIA
|
|
|
subjects affected / exposed
|
6 / 326 (1.84%) |
1 / 166 (0.60%) |
occurrences all number
|
6 |
1 |
DYSGEUSIA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
3 |
FINE MOTOR SKILL DYSFUNCTION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
HEADACHE
|
|
|
subjects affected / exposed
|
101 / 326 (30.98%) |
36 / 166 (21.69%) |
occurrences all number
|
142 |
49 |
HYPERREFLEXIA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
HYPOAESTHESIA
|
|
|
subjects affected / exposed
|
4 / 326 (1.23%) |
2 / 166 (1.20%) |
occurrences all number
|
4 |
2 |
INTENTION TREMOR
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
LETHARGY
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
MENTAL IMPAIRMENT
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
MIGRAINE
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
1 / 166 (0.60%) |
occurrences all number
|
2 |
1 |
MONOPARESIS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
MUSCLE CONTRACTIONS INVOLUNTARY
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
MUSCLE SPASTICITY
|
|
|
subjects affected / exposed
|
7 / 326 (2.15%) |
1 / 166 (0.60%) |
occurrences all number
|
7 |
1 |
NEURALGIA
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
NEUROLOGICAL DECOMPENSATION
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
NEUROPATHY PERIPHERAL
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
PARAESTHESIA
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
1 / 166 (0.60%) |
occurrences all number
|
3 |
1 |
PAROSMIA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
PERONEAL NERVE PALSY
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
POOR QUALITY SLEEP
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
2 / 166 (1.20%) |
occurrences all number
|
1 |
2 |
PRESYNCOPE
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
RADIAL NERVE PALSY
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
RESTLESS LEGS SYNDROME
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
SCIATICA
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
1 / 166 (0.60%) |
occurrences all number
|
2 |
1 |
SOMNOLENCE
|
|
|
subjects affected / exposed
|
6 / 326 (1.84%) |
3 / 166 (1.81%) |
occurrences all number
|
6 |
3 |
SPEECH DISORDER
|
|
|
subjects affected / exposed
|
4 / 326 (1.23%) |
1 / 166 (0.60%) |
occurrences all number
|
5 |
1 |
SYNCOPE
|
|
|
subjects affected / exposed
|
8 / 326 (2.45%) |
2 / 166 (1.20%) |
occurrences all number
|
8 |
3 |
TASTE DISORDER
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
TENSION HEADACHE
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
0 / 166 (0.00%) |
occurrences all number
|
4 |
0 |
TREMOR
|
|
|
subjects affected / exposed
|
4 / 326 (1.23%) |
2 / 166 (1.20%) |
occurrences all number
|
4 |
2 |
Blood and lymphatic system disorders
|
|
|
ANAEMIA
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
1 / 166 (0.60%) |
occurrences all number
|
3 |
1 |
ANAEMIA MACROCYTIC
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
BASAL CELL CARCINOMA
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
3 |
0 |
BENIGN NEOPLASM OF THYROID GLAND
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
BOWEN'S DISEASE
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
HYPOPHARYNGEAL CANCER
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
INVASIVE DUCTAL BREAST CARCINOMA
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
LEUKOCYTOSIS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
LEUKOPENIA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
LYMPHADENITIS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
LYMPHOPENIA
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
MYELOPROLIFERATIVE NEOPLASM
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
NORMOCYTIC ANAEMIA
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
SCHWANNOMA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
SQUAMOUS CELL CARCINOMA OF SKIN
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
Ear and labyrinth disorders
|
|
|
EAR PAIN
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
TINNITUS
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
0 / 166 (0.00%) |
occurrences all number
|
5 |
0 |
VERTIGO
|
|
|
subjects affected / exposed
|
6 / 326 (1.84%) |
3 / 166 (1.81%) |
occurrences all number
|
6 |
3 |
VERTIGO POSITIONAL
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
Eye disorders
|
|
|
BORDERLINE GLAUCOMA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
CATARACT
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
CONJUNCTIVAL HAEMORRHAGE
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
DIPLOPIA
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
0 / 166 (0.00%) |
occurrences all number
|
3 |
0 |
DRY EYE
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
ENTROPION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
EYE DISCHARGE
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
EYE HAEMATOMA
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
EYE INFLAMMATION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
EYE IRRITATION
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
0 / 166 (0.00%) |
occurrences all number
|
3 |
0 |
EYE PAIN
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
EYE SWELLING
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
EYELID CYST
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
GLAUCOMA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
IRITIS
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
LACRIMATION INCREASED
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
MACULAR DEGENERATION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
VISION BLURRED
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
Gastrointestinal disorders
|
|
|
ABDOMINAL DISCOMFORT
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
4 / 166 (2.41%) |
occurrences all number
|
3 |
4 |
ABDOMINAL DISTENSION
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
0 / 166 (0.00%) |
occurrences all number
|
4 |
0 |
ABDOMINAL PAIN
|
|
|
subjects affected / exposed
|
12 / 326 (3.68%) |
2 / 166 (1.20%) |
occurrences all number
|
13 |
2 |
ABDOMINAL PAIN LOWER
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
2 |
ABDOMINAL PAIN UPPER
|
|
|
subjects affected / exposed
|
7 / 326 (2.15%) |
2 / 166 (1.20%) |
occurrences all number
|
7 |
2 |
APHTHOUS ULCER
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
CONSTIPATION
|
|
|
subjects affected / exposed
|
38 / 326 (11.66%) |
21 / 166 (12.65%) |
occurrences all number
|
41 |
22 |
DENTAL CARIES
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
DENTAL DISCOMFORT
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
DIARRHOEA
|
|
|
subjects affected / exposed
|
26 / 326 (7.98%) |
14 / 166 (8.43%) |
occurrences all number
|
31 |
18 |
DRY MOUTH
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
1 / 166 (0.60%) |
occurrences all number
|
3 |
1 |
DYSPEPSIA
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
6 / 166 (3.61%) |
occurrences all number
|
4 |
7 |
DYSPHAGIA
|
|
|
subjects affected / exposed
|
47 / 326 (14.42%) |
27 / 166 (16.27%) |
occurrences all number
|
55 |
31 |
ENTERITIS
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
ERUCTATION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
FLATULENCE
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
1 / 166 (0.60%) |
occurrences all number
|
2 |
1 |
FOOD POISONING
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
GASTRIC HYPERMOTILITY
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
GASTRIC ULCER
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
GASTRITIS
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
2 / 166 (1.20%) |
occurrences all number
|
3 |
2 |
GASTROINTESTINAL PAIN
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
2 / 166 (1.20%) |
occurrences all number
|
1 |
2 |
GASTROOESOPHAGEAL REFLUX DISEASE
|
|
|
subjects affected / exposed
|
7 / 326 (2.15%) |
3 / 166 (1.81%) |
occurrences all number
|
7 |
3 |
HIATUS HERNIA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
HYPOAESTHESIA ORAL
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
INTESTINAL OBSTRUCTION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
IRRITABLE BOWEL SYNDROME
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
LIP SWELLING
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
MOUTH ULCERATION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
NAUSEA
|
|
|
subjects affected / exposed
|
29 / 326 (8.90%) |
15 / 166 (9.04%) |
occurrences all number
|
35 |
17 |
ODYNOPHAGIA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
ORAL MUCOSAL BLISTERING
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
RETCHING
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
SALIVARY GLAND ENLARGEMENT
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
SALIVARY HYPERSECRETION
|
|
|
subjects affected / exposed
|
22 / 326 (6.75%) |
9 / 166 (5.42%) |
occurrences all number
|
23 |
10 |
TONGUE ULCERATION
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
TOOTHACHE
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
2 |
VOMITING
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
5 / 166 (3.01%) |
occurrences all number
|
2 |
6 |
Skin and subcutaneous tissue disorders
|
|
|
ACNE
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
ALOPECIA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
BLISTER
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
DECUBITUS ULCER
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
0 / 166 (0.00%) |
occurrences all number
|
4 |
0 |
DERMATITIS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
DERMATITIS CONTACT
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
DRY SKIN
|
|
|
subjects affected / exposed
|
5 / 326 (1.53%) |
2 / 166 (1.20%) |
occurrences all number
|
5 |
2 |
DYSHIDROTIC ECZEMA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
ECZEMA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
ERYTHEMA
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
1 / 166 (0.60%) |
occurrences all number
|
2 |
1 |
HYPERHIDROSIS
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
2 / 166 (1.20%) |
occurrences all number
|
2 |
2 |
INGROWING NAIL
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
MILIARIA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
NIGHT SWEATS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
PIGMENTATION DISORDER
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
PRURITUS
|
|
|
subjects affected / exposed
|
10 / 326 (3.07%) |
4 / 166 (2.41%) |
occurrences all number
|
10 |
4 |
RASH
|
|
|
subjects affected / exposed
|
11 / 326 (3.37%) |
6 / 166 (3.61%) |
occurrences all number
|
11 |
8 |
RASH MACULAR
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
RASH MACULO-PAPULAR
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
RASH PAPULAR
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
SEBORRHOEA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
SEBORRHOEIC DERMATITIS
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
0 / 166 (0.00%) |
occurrences all number
|
3 |
0 |
SKIN EXFOLIATION
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
2 / 166 (1.20%) |
occurrences all number
|
0 |
2 |
SKIN IRRITATION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
3 |
1 |
Renal and urinary disorders
|
|
|
ACUTE KIDNEY INJURY
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
BLADDER DYSFUNCTION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
BLADDER PAIN
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
BLADDER SPASM
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
CHROMATURIA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
HAEMATURIA
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
3 / 166 (1.81%) |
occurrences all number
|
0 |
4 |
HYPERTONIC BLADDER
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
2 / 166 (1.20%) |
occurrences all number
|
1 |
2 |
INCONTINENCE
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
LEUKOCYTURIA
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
MICTURITION URGENCY
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
NEPHROLITHIASIS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
2 / 166 (1.20%) |
occurrences all number
|
1 |
2 |
NOCTURIA
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
POLLAKIURIA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
POLYURIA
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
PROTEINURIA
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
RENAL COLIC
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
RENAL FAILURE
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
RENAL PAIN
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
URGE INCONTINENCE
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
URINARY INCONTINENCE
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
1 / 166 (0.60%) |
occurrences all number
|
2 |
1 |
URINARY RETENTION
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
3 / 166 (1.81%) |
occurrences all number
|
3 |
3 |
URINE ABNORMALITY
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
Endocrine disorders
|
|
|
DIABETES INSIPIDUS
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
Musculoskeletal and connective tissue disorders
|
|
|
ARTHRALGIA
|
|
|
subjects affected / exposed
|
13 / 326 (3.99%) |
9 / 166 (5.42%) |
occurrences all number
|
15 |
9 |
ARTHRITIS
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
1 / 166 (0.60%) |
occurrences all number
|
3 |
1 |
BACK PAIN
|
|
|
subjects affected / exposed
|
14 / 326 (4.29%) |
7 / 166 (4.22%) |
occurrences all number
|
16 |
11 |
BONE PAIN
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
BURSITIS
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
COCCYDYNIA
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
1 / 166 (0.60%) |
occurrences all number
|
3 |
1 |
EXOSTOSIS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
FRACTURE PAIN
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
GROIN PAIN
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
2 / 166 (1.20%) |
occurrences all number
|
1 |
2 |
JOINT HYPEREXTENSION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
JOINT NOISE
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
JOINT SWELLING
|
|
|
subjects affected / exposed
|
7 / 326 (2.15%) |
0 / 166 (0.00%) |
occurrences all number
|
7 |
0 |
LIMB MASS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
MOBILITY DECREASED
|
|
|
subjects affected / exposed
|
4 / 326 (1.23%) |
1 / 166 (0.60%) |
occurrences all number
|
5 |
1 |
MUSCLE CONTRACTURE
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
MUSCLE FATIGUE
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
MUSCLE SPASMS
|
|
|
subjects affected / exposed
|
17 / 326 (5.21%) |
7 / 166 (4.22%) |
occurrences all number
|
21 |
8 |
MUSCLE TIGHTNESS
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
MUSCLE TWITCHING
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
MUSCULAR WEAKNESS
|
|
|
subjects affected / exposed
|
31 / 326 (9.51%) |
18 / 166 (10.84%) |
occurrences all number
|
39 |
18 |
MUSCULOSKELETAL CHEST PAIN
|
|
|
subjects affected / exposed
|
6 / 326 (1.84%) |
1 / 166 (0.60%) |
occurrences all number
|
6 |
1 |
MUSCULOSKELETAL PAIN
|
|
|
subjects affected / exposed
|
14 / 326 (4.29%) |
8 / 166 (4.82%) |
occurrences all number
|
17 |
8 |
MUSCULOSKELETAL STIFFNESS
|
|
|
subjects affected / exposed
|
4 / 326 (1.23%) |
1 / 166 (0.60%) |
occurrences all number
|
4 |
1 |
MYALGIA
|
|
|
subjects affected / exposed
|
4 / 326 (1.23%) |
3 / 166 (1.81%) |
occurrences all number
|
4 |
3 |
NECK PAIN
|
|
|
subjects affected / exposed
|
10 / 326 (3.07%) |
6 / 166 (3.61%) |
occurrences all number
|
11 |
6 |
PAIN IN EXTREMITY
|
|
|
subjects affected / exposed
|
24 / 326 (7.36%) |
6 / 166 (3.61%) |
occurrences all number
|
28 |
6 |
PAIN IN JAW
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
1 / 166 (0.60%) |
occurrences all number
|
2 |
1 |
PERIARTHRITIS
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
1 / 166 (0.60%) |
occurrences all number
|
4 |
1 |
POSTURE ABNORMAL
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
ROTATOR CUFF SYNDROME
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
SPINAL PAIN
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
TENDONITIS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
TENOSYNOVITIS STENOSANS
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
Infections and infestations
|
|
|
ALVEOLAR OSTEITIS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
BACTERIAL INFECTION
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
BACTERIURIA
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
BLASTOMYCOSIS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
BRONCHITIS
|
|
|
subjects affected / exposed
|
7 / 326 (2.15%) |
4 / 166 (2.41%) |
occurrences all number
|
8 |
4 |
CANDIDA INFECTION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
CATHETER SITE INFECTION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
CELLULITIS
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
2 / 166 (1.20%) |
occurrences all number
|
0 |
2 |
CLOSTRIDIUM DIFFICILE INFECTION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
CONJUNCTIVITIS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
COVID-19
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
CYSTITIS
|
|
|
subjects affected / exposed
|
4 / 326 (1.23%) |
4 / 166 (2.41%) |
occurrences all number
|
6 |
4 |
EAR INFECTION
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
3 / 166 (1.81%) |
occurrences all number
|
3 |
3 |
ERYSIPELAS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
EYE INFECTION
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
FUNGAL INFECTION
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
FUNGAL SKIN INFECTION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
2 |
1 |
FURUNCLE
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
GASTROENTERITIS
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
2 / 166 (1.20%) |
occurrences all number
|
2 |
2 |
GASTROENTERITIS VIRAL
|
|
|
subjects affected / exposed
|
6 / 326 (1.84%) |
2 / 166 (1.20%) |
occurrences all number
|
7 |
2 |
GASTROINTESTINAL INFECTION
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
GENITOURINARY TRACT INFECTION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
HELMINTHIC INFECTION
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
HERPES ZOSTER
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
HORDEOLUM
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
IMPETIGO
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
INFECTED BITE
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
INFECTION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
INFLUENZA
|
|
|
subjects affected / exposed
|
4 / 326 (1.23%) |
0 / 166 (0.00%) |
occurrences all number
|
4 |
0 |
LARYNGITIS
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
2 / 166 (1.20%) |
occurrences all number
|
0 |
2 |
LOCALISED INFECTION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
LOWER RESPIRATORY TRACT INFECTION
|
|
|
subjects affected / exposed
|
4 / 326 (1.23%) |
0 / 166 (0.00%) |
occurrences all number
|
5 |
0 |
MALASSEZIA INFECTION
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
MEDICAL DEVICE SITE INFECTION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
NAIL INFECTION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
NASOPHARYNGITIS
|
|
|
subjects affected / exposed
|
52 / 326 (15.95%) |
26 / 166 (15.66%) |
occurrences all number
|
62 |
31 |
ORAL CANDIDIASIS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
ORAL FUNGAL INFECTION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
ORAL HERPES
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
OROPHARYNGEAL CANDIDIASIS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
OTITIS MEDIA CHRONIC
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
PERIODONTITIS
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
PHARYNGITIS
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
2 / 166 (1.20%) |
occurrences all number
|
2 |
2 |
PHARYNGITIS STREPTOCOCCAL
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
PNEUMONIA
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
5 / 166 (3.01%) |
occurrences all number
|
2 |
5 |
POST PROCEDURAL INFECTION
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
1 / 166 (0.60%) |
occurrences all number
|
2 |
1 |
POSTOPERATIVE WOUND INFECTION
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
PULPITIS DENTAL
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
2 / 166 (1.20%) |
occurrences all number
|
2 |
3 |
PYELITIS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
RESPIRATORY TRACT INFECTION
|
|
|
subjects affected / exposed
|
7 / 326 (2.15%) |
2 / 166 (1.20%) |
occurrences all number
|
7 |
2 |
RHINITIS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
2 / 166 (1.20%) |
occurrences all number
|
1 |
3 |
ROOT CANAL INFECTION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
SIALOADENITIS
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
SINUSITIS
|
|
|
subjects affected / exposed
|
8 / 326 (2.45%) |
3 / 166 (1.81%) |
occurrences all number
|
8 |
3 |
STAPHYLOCOCCAL INFECTION
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
STOMA SITE INFECTION
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
TONGUE FUNGAL INFECTION
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
TONSILLITIS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
2 / 166 (1.20%) |
occurrences all number
|
1 |
2 |
TOOTH ABSCESS
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
TOOTH INFECTION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
UPPER RESPIRATORY TRACT INFECTION
|
|
|
subjects affected / exposed
|
13 / 326 (3.99%) |
5 / 166 (3.01%) |
occurrences all number
|
16 |
5 |
URINARY TRACT INFECTION
|
|
|
subjects affected / exposed
|
25 / 326 (7.67%) |
17 / 166 (10.24%) |
occurrences all number
|
31 |
22 |
URINARY TRACT INFECTION BACTERIAL
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
VIRAL INFECTION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
VIRAL UPPER RESPIRATORY TRACT INFECTION
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
1 / 166 (0.60%) |
occurrences all number
|
2 |
1 |
VULVOVAGINAL MYCOTIC INFECTION
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
Metabolism and nutrition disorders
|
|
|
CACHEXIA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
1 / 166 (0.60%) |
occurrences all number
|
1 |
1 |
DECREASED APPETITE
|
|
|
subjects affected / exposed
|
10 / 326 (3.07%) |
5 / 166 (3.01%) |
occurrences all number
|
10 |
5 |
DEHYDRATION
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
2 / 166 (1.20%) |
occurrences all number
|
1 |
2 |
DIABETES MELLITUS
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
GOUT
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
HYPERGLYCAEMIA
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
HYPERKALAEMIA
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
2 / 166 (1.20%) |
occurrences all number
|
0 |
3 |
HYPERLIPIDAEMIA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
HYPOKALAEMIA
|
|
|
subjects affected / exposed
|
3 / 326 (0.92%) |
2 / 166 (1.20%) |
occurrences all number
|
3 |
2 |
HYPONATRAEMIA
|
|
|
subjects affected / exposed
|
2 / 326 (0.61%) |
0 / 166 (0.00%) |
occurrences all number
|
2 |
0 |
HYPOPHAGIA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
HYPOVOLAEMIA
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
IRON DEFICIENCY
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |
MALNUTRITION
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
POLYDIPSIA
|
|
|
subjects affected / exposed
|
0 / 326 (0.00%) |
1 / 166 (0.60%) |
occurrences all number
|
0 |
1 |
VITAMIN B12 DEFICIENCY
|
|
|
subjects affected / exposed
|
1 / 326 (0.31%) |
0 / 166 (0.00%) |
occurrences all number
|
1 |
0 |